End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain
<p><strong>Background</p></strong> The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2024
|
| _version_ | 1826315012924243968 |
|---|---|
| author | Whitaker, HJ Willam, N Cottrell, S Goudie, R Andrews, N Evans, J Moore, C Agrawal, U Hassell, K Gunson, R Zitha, J Anand, S Sebastian-Pillai, P Kalapotharakou, P Okusi, C Hoschler, K Jamie, G Kele, B Hamilton, M Couzens, A Quinot, C Pheasant, K Byford, R Marsh, K Robertson, C de Lusignan, S Williams, C Zambon, M McMenamin, J Watson, CH |
| author_facet | Whitaker, HJ Willam, N Cottrell, S Goudie, R Andrews, N Evans, J Moore, C Agrawal, U Hassell, K Gunson, R Zitha, J Anand, S Sebastian-Pillai, P Kalapotharakou, P Okusi, C Hoschler, K Jamie, G Kele, B Hamilton, M Couzens, A Quinot, C Pheasant, K Byford, R Marsh, K Robertson, C de Lusignan, S Williams, C Zambon, M McMenamin, J Watson, CH |
| author_sort | Whitaker, HJ |
| collection | OXFORD |
| description | <p><strong>Background</p></strong>
The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.
<p><strong>
Methods</p></strong>
End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.
<p><strong>
Methods</p></strong>
Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).
<p><strong>
Conclusion</p></strong>
The paper provides evidence of moderate influenza VE in 2022/23. |
| first_indexed | 2024-12-09T03:18:19Z |
| format | Journal article |
| id | oxford-uuid:544c7951-7d15-47e1-9c32-da6decd7c4eb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:18:19Z |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:544c7951-7d15-47e1-9c32-da6decd7c4eb2024-10-31T14:51:07ZEnd of 2022/23 season influenza vaccine effectiveness in primary care in Great BritainJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:544c7951-7d15-47e1-9c32-da6decd7c4ebEnglishSymplectic ElementsWiley2024Whitaker, HJWillam, NCottrell, SGoudie, RAndrews, NEvans, JMoore, CAgrawal, UHassell, KGunson, RZitha, JAnand, SSebastian-Pillai, PKalapotharakou, POkusi, CHoschler, KJamie, GKele, BHamilton, MCouzens, AQuinot, CPheasant, KByford, RMarsh, KRobertson, Cde Lusignan, SWilliams, CZambon, MMcMenamin, JWatson, CH<p><strong>Background</p></strong> The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom. <p><strong> Methods</p></strong> End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders. <p><strong> Methods</p></strong> Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%). <p><strong> Conclusion</p></strong> The paper provides evidence of moderate influenza VE in 2022/23. |
| spellingShingle | Whitaker, HJ Willam, N Cottrell, S Goudie, R Andrews, N Evans, J Moore, C Agrawal, U Hassell, K Gunson, R Zitha, J Anand, S Sebastian-Pillai, P Kalapotharakou, P Okusi, C Hoschler, K Jamie, G Kele, B Hamilton, M Couzens, A Quinot, C Pheasant, K Byford, R Marsh, K Robertson, C de Lusignan, S Williams, C Zambon, M McMenamin, J Watson, CH End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title | End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title_full | End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title_fullStr | End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title_full_unstemmed | End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title_short | End of 2022/23 season influenza vaccine effectiveness in primary care in Great Britain |
| title_sort | end of 2022 23 season influenza vaccine effectiveness in primary care in great britain |
| work_keys_str_mv | AT whitakerhj endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT willamn endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT cottrells endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT goudier endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT andrewsn endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT evansj endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT moorec endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT agrawalu endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT hassellk endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT gunsonr endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT zithaj endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT anands endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT sebastianpillaip endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT kalapotharakoup endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT okusic endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT hoschlerk endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT jamieg endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT keleb endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT hamiltonm endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT couzensa endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT quinotc endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT pheasantk endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT byfordr endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT marshk endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT robertsonc endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT delusignans endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT williamsc endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT zambonm endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT mcmenaminj endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain AT watsonch endof202223seasoninfluenzavaccineeffectivenessinprimarycareingreatbritain |